When second-line hormonal therapy fails to control endometriosis-related pain, an escalated approach is warranted. This protocol addresses the management step taken after established second-line options have not delivered adequate pain relief.
Second-line therapy — which includes a GnRH receptor agonist (leuprolide depot, goserelin, or nafarelin) with add-back therapy; a GnRH receptor antagonist (elagolix, or the relugolix/estradiol/norethindrone combination tablet); or danazol — did not achieve the expected improvement in dysmenorrhea and nonmenstrual pelvic pain. Inadequate response to this line triggers escalation.
For severe, refractory endometriosis-related pain, the next therapeutic category involves an aromatase inhibitor used together with ovarian suppression. The full protocol — combination strategy, clinical considerations, and sequencing — is available via the link below.
Aromatase inhibitors are reserved for patients with severe, refractory, endometriosis-related pain.
Aromatase inhibitors are often prescribed in combination with a GnRH receptor agonist or combined oral contraceptive to downregulate the ovaries and suppress follicular development.
View source ↗